ArticleCancer causes & control : CCC2026
Impact of the COVID-19 pandemic and its measures on one-year and three-year cancer survival using Swiss cantonal cancer registry data.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe COVID-19 pandemic and associated measures negatively impacted health outcomes of patients with severe diseases. This study investigated the short- and intermediate-term impact of the pandemic on cancer survival.
methodsThis study was based on cancer registry data of the Swiss cantons of Zurich and Zug from 2018 to 2021. Observed and relative one- and three-year survival were calculated based on lifetables for the population covered by the registry. Multivariable Royston Parmar survival regression models were fitted to compare survival before (2018/2019) and during the pandemic (2020, 2021). For patients diagnosed during the pandemic, a counterfactual analysis was conducted. Analyses were performed for overall cancer and the five most common cancer types.
resultsOverall, 32 826 cancer cases were included. One- and three-year survival for all-cancer continuously increased from 2018 to 2021. Compared to pre-pandemic, the hazard of death was lower for all-cancer during the pandemic (2020: Hazard Ratio 0.93 [95% Confidence Interval 0.89, 0.96]; 2021: 0.91 [0.87, 0.94]) and for skin melanoma in 2021 (0.79 [0.62, 0.98]), but higher for colorectal cancer during the pandemic (2020: 1.17 [1.03, 1.32]; 2021: 1.24 [1.09, 1.40]). Observed one-year survival for all-cancer, female breast, and prostate cancer was higher in 2021 than predicted. In 2020, observed one-year survival of colorectal cancer and three-year survival of female breast cancer were lower than predicted.
conclusionThe COVID-19 pandemic appears to have had only a minimal impact on the overall increasing cancer survival trend in Switzerland, reflecting the robustness and resilience of the healthcare system.
Indexed as
Identifiers
42189265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.